Omnipod Insulin Pump Market to register an appreciable double-digit CAGR over 2017-2024, Europe to drive the global landscape

The recently announced strategic collaboration between omnipod insulin pump market behemoth, Insulet Corporation with Ascensia Diabetes Care is quite a remarkable instance that demonstrates the product diversification trends being observed across the omnipod insulin pump industry landscape. Reportedly, as per the latest agreement, Insulet’s next-generation Omnipod Dash™ System would be connected to Ascensia’s CONTOUR®NEXT ONE blood glucose monitoring system (BGMS). The integration of both the systems would apparently create an innovative insulin delivery system that is likely to assist diabetic populace in accurately recording blood glucose readings. Seemingly, the novel insulin delivery system goes on to underline the emergence of highly advanced products which would swamp the tubeless insulin pump market over the forthcoming years.

The rising prevalence of diabetic population across the globe has been one of the pivotal factors to have contributed significantly toward the omnipod insulin pump industry share augmentation. According to the statistics published by World Health Organization, diabetes would be the among the leading causes of casualties worldwide by the year 2030. In order to tackle this burgeoning healthcare-associated predicament, leading omnipod insulin pump market players have been concentrating on developing outcome based and more customized insulin pumps.

Tubeless Insulin Pump Market Size By Component, By Distribution Channel, Regional Outlook, Technology Development, Competitive Landscape & Forecast, 2017 – 2024” has been published by Global Market Insights. To understand the industry better, request a sample of this report @

Elaborating further, it is quite imperative to mention that omnipod insulin pumps not only eliminate the need of daily insulin injection dosage but also come with a range of progressive features such as portability and daily scheduling of insulin delivery. Moreover, these devices calculate the optimum requirement of insulin dosage based on food database and display blood sugar level as well. Apparently, owing to the aforementioned benefits of these glucose monitoring devices, the omnipod insulin pump market would undeniably establish itself as one of the most lucrative business verticals of the overall healthcare and medical devices industry in the near future.

In terms of geographical expansion, Europe has emerged as one of the most crucial hubs for the rapid advancement of the global omnipod insulin pump market. The presence of excellent healthcare infrastructure across the continent can be accredited for the swift pace of product penetration in nations along the likes of Germany and France. Apparently, the rising diabetic populace coupled with enhancement in medical services has ostensibly strengthened the Germany omnipod insulin pump industry share in the recent times. Moreover, an increase in deployment of novel technologies across the healthcare sector has favorably influenced the overall Germany tubeless insulin pump market which commanded close to 20% of the regional share in the year 2016, as per reliable estimates.

Although omnipod insulin pump technology is considered to be in a nascent stage when compared to traditional tubed insulin pumps, the accelerated pace of technological developments is bound to proliferate the omnipod insulin pump industry share in the ensuing years. Moreover, upcoming firms such as Johnson & Johnson, Spring Health Solutions, Cellnova, Abbott Diabetes Care, Valeritas Holding, Debiotech, Roche Holdings, Medtrum Technologies, and CeQur have been competing fiercely with established players like Insulet Corporation to enhance the existing insulin pump technology.

As a consequence, this growing rivalry among omnipod insulin pump market participants would prove advantageous to the overall business space over the forecast time frame. In fact, according to a study undertaken by Global Market Insights, Inc., the worldwide tubeless insulin pump industry is slated to witness exceptional progression in the forthcoming years, with a projected CAGR of 25% over 2017-2024.